ARC grant round pledges $70m to life sciences
17 November, 2004 by Renate KrelleThe latest round of Australian Research Council linkage and discovery grants, announced today, have allocated AUD$381 million over five years to more than 1300 new research projects from 2005.
In brief: Neuren; ACCC; Roche; QIC; Rockeby; Acrux
16 November, 2004 by Staff WritersNew Zealand biotech Neuren today lodged the prospectus for its mid-January IPO with ASIC, announcing that it will aim to raise AUD$15 million, giving it an indicative market capitalisation of AUD$40 million.
AusBiotech 2004: Macfarlane warns companies of coming struggle
10 November, 2004 by Iain Scott and Melissa TrudingerFederal Industry Minister Ian Macfarlane has warned the Australian biotechnology industry that it still has a lot of work to do to win over the public.
AusBiotech 2004: Don't hide within Australia's borders, Burrill warns Australian biotechs
09 November, 2004 by Renate KrelleThe drug-discovery industry -- pharma and biotech alike -- will suffer a sea-change as the age of personalised medicine begins, said Steve Burrill at Monday's opening of the 2004 AusBiotech conference in Brisbane.
Biosignal hires US tech-spruik experts
09 November, 2004 by Graeme O'NeillHospitals don't like to divulge how many surgical patients have been chronically infected by pathogenic, multi-drug resistant bacteria that haunt their surgical wards, but the problem is "major", according to Michael Oredsson, CEO and MD of Sydney biotech company Biosignal (ASX:BOS).
Peptech books record $28m profit
04 November, 2004 by Melissa TrudingerPeptech (ASX:PTD) has posted a record AUD$28.3 million net profit for the 2003-2004 financial year ending September 30, contrasting strongly with last year's $15.8 million loss.
Venter and crew set sail for Australian partnerships
03 November, 2004 by Renate KrelleRelaxed at the helm of his 95-foot yacht - the Sorcerer II -- on a brilliant Sydney morning, scientist and sailor J Craig Venter has started the Australian leg of his bid to circumnavigate the globe, sampling, sequencing and identifying microorganisms as he goes.
Life science VC up, but investment slows overall
01 November, 2004 by Renate KrelleThe life sciences sector once again received the largest slice of US venture capital investment in Q2 of 2004, according to a survey of the professional venture capital community. Investments in the sector amounted to US$1.26 billion -- 29 per cent of all venture capital invested.
Healthcare the focus of CSIRO's new IT centre
29 October, 2004 by Renate KrelleHealthcare projects like personal health monitoring and distance medical care will be core issues at CSIRO's new national ICT research centre.
Hong Kong's CK Life Sciences to invest $10m in Vic
28 October, 2004 by Melissa TrudingerHong Kong biotechnology company CK Life Sciences, part of the Cheung Kong group, is set to invest $10 million in R&D in Victoria, according to state premier Steve Bracks.
London calls BioComm, and Japan awaits
28 October, 2004 by Melissa TrudingerMelbourne-based licensing and business development group BioComm has opened an office in London to facilitate licensing and partnering activities in Europe.
NZ Roadshow: Signalling more cooperation
27 October, 2004 by Graeme O'NeillA leading New Zealand biotechnologist has urged Australian and New Zealand medical researchers to establish a trans-Tasman research consortium to explore the body's cell-signalling systems.
NZ Roadshow: Swim together or sink alone
27 October, 2004 by Graeme O'NeillThe Biosphere New Zealand Roadshow 2004 has hit the road in Melbourne, arguing the case for a strategic union of the biotechnology industries on either side of the Tasman Sea.
Optiscan wins FDA clearance for endomicrosope
27 October, 2004 by Renate KrelleOptiscan (ASX:OIL) has won earlier-than-expected clearance from the US Food and Drug Administration (FDA) for the flexible endomicroscope it is jointly developing with Pentax.
Optiscan wins CE Mark approval, waiting on FDA
18 October, 2004 by Renate KrelleOptiscan (ASX:OIL) has received European CE Mark approval for its flexible endo-microscope, jointly developed with Pentax. But the company and its Japanese marketing partner Pentax are awaiting a go-ahead from the US Food and Drug Administration before the marketing process gets underway.
